Histrelin acetate subcutaneous implant (Supprelin® LA)

Supprelin LA (histrelin acetate 50 mg subcutaneous implant) is covered only for children with the FDA‑approved indication of central precocious puberty; other indications are excluded. Authorization is for 12 months with the recommended 50 mg implant placed subcutaneously in the upper arm once every 12 months, and documentation of the CPP diagnosis and that the patient meets the FDA‑approved coverage criteria is required.

"Treatment of children with central precocious puberty (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.